Effect of endostatin on preventing postoperative progression of distant metastasis in a murine lung cancer model

Tumori

Volumn 97, Issue 6, 2011, Pages 787-793

  Wang, He Lan ^a   Ning, Tao ^a   Li, Mei ^a   Lu, Ze Jun ^a   Yan, Xi ^a   Peng, Qian ^a   Lei, Na ^a   Zhang, Hui ^a   Luo, Feng ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Endostatin; Lung cancer model; Postoperative progression; Remote metastasis

Indexed keywords

RECOMBINANT ENDOSTATIN; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTICLE; C57BL 6 MOUSE; CANCER GROWTH; CANCER MODEL; CANCER SURGERY; CANCER TRANSPLANTATION; CAPILLARY DENSITY; CONTROLLED STUDY; DISTANT METASTASIS; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; LEWIS CARCINOMA; LUNG METASTASIS; LUNG NODULE; LUNG WEIGHT; MICROVASCULATURE; MOUSE; NONHUMAN; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PRIMARY TUMOR; RANDOMIZATION; SURVIVAL TIME;

ANGIOGENESIS INHIBITORS; ANIMALS; CARCINOMA, LEWIS LUNG; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENDOSTATINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; POSTOPERATIVE PERIOD; RANDOM ALLOCATION; SECONDARY PREVENTION;

EID: 84863156168     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1700/1018.11097     Document Type: Article

References (38)

1. Junttila MR, Karnezis AN, Garcia D, Madriles F, Kortlever RM, Rostker F, Brown Swigart L, Pham DM, Seo Y, Evan GI, Martins CP: Selective activation of p53-mediated tumor suppression in high-grade tumors. Nature, 468: 519-520, 2010.
2. Pfannschmidt J, Muley T, Bülzebruck H, Hoffmann H, Dienemann H: Prognostic assessment after surgical resection for non-small cell lung cancer: Experiences in 2083 patients. Lung Cancer, 55: 371-377, 2007. (Pubitemid 46331863)
3. Hsiao YC, Kuo WH, Chen PN, Chang HR, Lin TH, Yang WE, Hsieh YS, Chu SC: Flavanone and 2-OH flavanone inhibit metastasis of lung cancer cells via down-regulation of proteinases activities and MAPK pathway. Chem Biol Interact, 167: 193-206, 2007.
4. Thomas JP, Arzoomanian RZ, Alberti D, Marnocha R, Lee F, Friedl A, Tutsch K, Dresen A, Geiger P, Pluda J, Fogler W, Schiller JH, Wilding G: Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol, 21: 223- 231, 2003.
5. Folkman J: Antiangiogenesis in cancer therapy - endostatin and its mechanisms of action. Exp Cell Res, 312: 594- 607, 2006.
6. Abdollahi A, Hahnfeldt P, Maercker C, Gröne HJ, Debus J, Ansorge W, Folkman J, Hlatky L, Huber PE: Endostatin's antiangiogenic signaling network.Mol Cell, 13: 649-663, 2004. (Pubitemid 38368123)
7. Faye C, Chautard E, Olsen BR, Ricard-Blum S: The first draft of the endostatin interaction network. J Biol Chem, 284: 22041-22047, 2009.
8. Cao Y: Endogenous angiogenesis inhibitors and their therapeutic implications. Int J Biochem Cell Biol, 33: 357-369, 2001.
9. Zhang PH, Qin J, Li AM, Ding XM, Yang-feng D, Rongcheng L: Inhibitory effects of recombinant human endostatin on the metastatic potential and invasiveness of hepatocellular carcinoma HCCLM6 cells in vitro. Nan Fang Yi Ke Da Xue Xue Bao, 28: 658-661, 2008.
10. Ni Q, Ji H, Zhao Z, Fan X, Xu C: Endostar, a modified endostatin inhibits non small cell lung cancer cell in vitro invasion through osteopontin-related mechanism. Eur J Pharmacol, 1: 1-6, 2009.
11. Calvo A, Yokoyama Y, Smith LE, Ali I, Shih SC, Feldman AL, Libutti SK, Sundaram R, Green JE: Inhibition of the mammary carcinoma angiogenic switch in C3(1)/SV40 transgenic mice by a mutated form of human endostatin. Int J Cancer, 101: 224-234, 2002. (Pubitemid 34970889)
12. Xia H, Luo LM, Fan YF, Tong WC, Wen JX: Inhibitory effect of recombinant human endostatin on angiogenesis and lung metastasis of mouse lung adenocarcinoma, LA795. Di Yi Jun Yi Da Xue Xue Bao, 23: 30-33, 2003.
13. Yao HC, Jin DJ, Sun YN, Ren MH, Li XD: Endostatin in the treatment of the transplantable model of human laryngeal squamous carcinoma in nude mice. Chinese Journal of Otorhinolaryngology, 39: 394-398, 2004.
14. Te Velde EA, Reijerkerk A, Brandsma D, Vogten JM, Wu Y, Kranenburg O, Voest EE, Gebbink M, Borel Rinkes IH: Early endostatin treatment inhibits metastatic seeding of murine colorectal cancer cells in the liver and their adhesion to endothelial cells. Br J Cancer, 92: 729-735, 2005. (Pubitemid 40460610)
15. Sauter BV, Martinet O, Zhang WJ, Mandeli J, Woo SL: Adenovirus- mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases. Proc Natl Acad Sci USA, 97: 4802-4807, 2000. (Pubitemid 30238638)
16. Zhang GM, Wang SJ, Ren MH: Study on purification and biological activity of recombinant human endostatin. Bulletin of Chinese Cancer, 14: 122-125, 2005.
17. Beecken WD, Engl T, Jonas D, Blaheta RA: Expression of angiogenesis inhibitors in human bladder cancer may explain rapid metastatic progression after radical cystectomy. Int J Mol Med, 23: 261-266, 2009.
18. Tsunemi T, Nagoya S, Kaya M, Kawaguchi S, Wada T, Yamashita T, Ishii S: Postoperative progression of pulmonary metastasis in osteosarcoma. Clin Orthop Relat Res, 407: 159-166, 2003. (Pubitemid 36176505)
19. Kaya M, Wada T, Nagoya S, Kawaguchi S, Isu K, Yamashita T: Concomitant tumour resistance in patients with osteosarcoma. A clue to a new therapeutic strategy for osteosarcoma. J Bone Joint Surg Br, 86: 143-147, 2004. (Pubitemid 38128722)
20. Jiang XD, Dai P, Wu J, Song DA, Yu JM: Inhibitory effect of radiotherapy combined with weekly recombinant human endostatin on the human pulmonary adenocarcinoma A549 xenografts in nude mice. Lung Cancer, 72: 165-171, 1987.
21. Zhu LP, Xing J, Wang QX, Kou L, Li C, Hu B, Wu ZW, Wang JJ, Xu GX: Therapeutic efficacy of recombinant human endostatin combined with chemotherapeutics in mice-transplanted tumors. Eur J Pharmacol, 617: 23-27, 2009.
22. Monestiroli S, Mancuso P, Burlini A, Pruneri G, Dell'Agnola C, Gobbi A, Martinelli G, Bertolini F: Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res, 61: 4341-4344, 2001. (Pubitemid 32685756)
23. Weidner N, Semple JP, Welch WR, Folkman J: Tumor angio-genesis and metastasis: correlation in invasive breast carcinoma. N Engl J Med, 324: 1-8, 1991.
24. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med, 1: 27-31, 1995.
25. Dhanabal M, Ramchandran R, Waterman MJ, Lu H, Knebelmann B, Segal M, Sukhatme VP: Endostatin induces endothelial cell apoptosis. J Biol Chem, 274: 11721-11726, 1999.
26. Skovseth DK, Veuger MJ, Sorensen DR, De Angelis PM, Haraldsen G: Endostatin dramatically inhibits endothelial cell migration, vascular morphogenesis, and perivascular cell recruitment in vivo. Blood, 105: 1044-1051, 2005. (Pubitemid 40170874)
27. Pantel K, Brakenhoff RH: Dissecting the metastatic cascade. Nat Rev Cancer, 4: 448-456, 2004. (Pubitemid 38745530)
28. Mendoza M, Khanna C: Revisiting the seed and soil in cancer metastasis. Int J Biochem Cell Biol, 41: 1452-1462, 2009.
29. Sun X, Qiao H, Jiang H, Zhi X, Liu F, Wang J, Liu M, Dong D, Kanwar JR, Xu R, Krissansen GW: Intramuscular delivery of antiangiogenic genes suppresses secondary metastases after removal of primary tumors. Cancer Gene Ther, 12: 35- 45, 2005.
30. Ribatti D: Antiangiogenic therapy accelerates tumor metastasis. Leuk Res, 35: 24-26, 2011.
31. Kaya M, Wada T, Nagoya S, Yamashita T: Prevention of postoperative progression of pulmonary metastases in osteosarcoma by antiangiogenic therapy using endostatin. J Orthop Sci, 12: 562-567, 2007. (Pubitemid 350190510)
32. Kuroiwa M, Takeuchi T, Lee JH, Yoshizawa J, Hirato J, Kaneko S, Choi SH, Suzuki N, Ikeda H, Tsuchida Y: Continuous versus intermittent administration of human endostatin in xenografted human neuroblastoma. J Pediatr Surg, 38: 1499-1505, 2003. (Pubitemid 37238794)
33. Ning T, Yan X, Lu ZJ, Wang GP, Zhang NG, Yang JL, Jiang SS, Wu Y, Yang L, Guan YS, Luo F: Gene therapy with the angio-genesis inhibitor endostatin in an orthotopic lung cancer murine model. Hum Gene Ther, 20: 103-111, 2009.
34. Saarela J, Ylikärppä R, Rehn M, Purmonen S, Pihlajaniemi T: Complete primary structure of two variant forms of human type XVIII collagen and tissue-specific diffences in the expression of the corresponding transcript. Matrix Biol, 16: 319-328, 1998. (Pubitemid 28052585)
35. Weidner N: Measuring intratumoral microvessel density. Methods Enzymol, 444: 305-323, 2008.
36. Mancuso P, Burlini A, Pruneri G, Goldhirsch A, Martinelli G, Bertolini F: Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood, 97: 3658-3661, 2001.
37. Wierzbowska A, Robak T, Krawczy ska A, Wrzesie -Ku A, Pluta A, Cebula B, Smolewski P: Circulating endothelial cells in patients with acute myeloid leukemia. Eur J Haematol, 75: 492-497, 2005.
38. Rowand JL, Martin G, Doyle GV, Miller MC, Pierce MS, Connelly MC, Rao C, Terstappen LW: Endothelial cells in peripheral blood of healthy subjects and patients with metastatic carcinomas. Cytometry A, 71: 105-113, 2007. (Pubitemid 46238939)